Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy
July 17 2008 - 8:30AM
PR Newswire (US)
- Ablative Solution to Treat Deep Wrinkles and Significant Photo
Damage WESTFORD, Mass., July 17 /PRNewswire-FirstCall/ -- Cynosure,
Inc. (NASDAQ:CYNO), a leading developer and manufacturer of a broad
array of light-based aesthetic treatment systems, today launched
the Affirm CO2(TM), an ablative workstation with a proprietary
scanning delivery system that combines ablative CO2 skin
resurfacing and rejuvenation in a single laser system. "Affirm CO2
is a dynamic platform to address deep wrinkles, significant
photoaging, severe scar damage and other difficult-to-treat skin
conditions," said Cynosure President and Chief Executive Officer
Michael Davin. "Our newest flagship workstation integrates a carbon
dioxide laser, with Micro Ablative scanning technology and is
considered the most effective treatment option for deep wrinkles.
The result is a system that helps patients look years younger with
minimal downtime, and affords physicians substantial flexibility in
treatment options. The Affirm CO2 system offers a range of settings
that enable physicians to customize the treatment based on the
aesthetic goals and downtime expectations of individual patients."
The Affirm CO2 system with Micro Ablative scanning technology is
the newest flagship addition to Cynosure's Affirm(TM) family of
products for anti-aging indications. The original Affirm
Workstation, introduced in 2006, delivers a non-ablative treatment
designed to produce progressive results in patients with fine to
moderate wrinkles and sun-damaged skin. By contrast, the Affirm CO2
workstation uses an ablative approach to target the epidermal and
dermal layer with the objective of treating dyschromia, deep
wrinkles and significant photoaging. According to the Millennium
Research Group, the skin rejuvenation market is expected to grow
annually by 18 percent, resulting in a $239 million industry by
2010, with approximately 4.4 million procedures performed per year
by 2010. "The Affirm CO2 targets a large and growing market of
consumers for whom age is not an impediment to vitality or a
youthful appearance," Davin said. "In a country where 12,000 people
turn 50 every day, and the population over the age of 55 is
expected to grow 60% over the next 20 years, we believe the market
opportunity for Cynosure is significant." "With power up to 30
watts and an adjustable pulse duration between 0.2 and 2 milli
seconds, Affirm CO2 offers the versatility of performing a light to
aggressive treatment with a single laser," said Bruce Katz, M.D.,
Clinical Professor of Dermatology at The Mount Sinai School of
Medicine, Director of the Cosmetic Surgery & Laser Clinic at
Mount Sinai Medical Center and Director of the Juva Skin &
Laser Center in New York. "Another important benefit is the range
of scanning options, which enable users not only to shorten
treatment time, but to provide uniform coverage across the entire
treatment area." Initial U.S. shipments of Affirm CO2 are expected
to begin in the third quarter of 2008. About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems
that are used by physicians and other practitioners to perform
non-invasive and minimally invasive procedures to remove hair,
treat vascular lesions, rejuvenate skin through the treatment of
shallow vascular and pigmented lesions, laser lipolysis and
temporarily reduce the appearance of cellulite. Cynosure's products
include a broad range of laser and other light-based energy
sources, including Alexandrite, pulsed dye, Nd:YAG and diode
lasers, as well as intense pulsed light. Cynosure was founded in
1991. For corporate or product information, contact Cynosure at
800-886-2966, or visit http://www.cynosure.com/. Forward-Looking
Statements Any statements in this press release about future
expectations, plans and prospects for Cynosure, Inc., including
statements about the company's expectations regarding the
performance and market acceptance of the Affirm CO2 and future
financial performance, as well as other statements containing the
words "believes," "anticipates," "plans," "expects," "will" and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including market acceptance of the Affirm CO2, Cynosure's
reliance on sole source suppliers, the inability to accurately
predict the timing or outcome of regulatory decisions, changes in
consumer preferences, competition in the aesthetic laser industry,
economic, market, technological and other factors discussed in
Cynosure's most recent Annual Report on Form 10-K and Form 10-Q
each of which is filed with the Securities and Exchange Commission.
In addition, the forward-looking statements included in this press
release represent Cynosure's views as of the date of this press
release. Cynosure anticipates that subsequent events and
developments will cause its views to change. However, while
Cynosure may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. These forward-looking statements should not be relied
upon as representing Cynosure's views as of any date subsequent to
the date of this press release. Contact: Scott Solomon Vice
President Sharon Merrill Associates, Inc. 617-542-5300 DATASOURCE:
Cynosure, Inc. CONTACT: Scott Solomon, Vice President of Sharon
Merrill Associates, Inc. for Cynosure, Inc., +1-617-542-5300, Web
site: http://www.cynosure.com/
Copyright
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From May 2024 to Jun 2024
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jun 2023 to Jun 2024